Hetero Labs Limited acquires Tarbis Farma in Spain
The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and a seamless entry into the Retail, Hospital and Tender business channels in Spain.
2nd January 2019: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that its European subsidiary Amarox Limited has acquired Tarbis Farma, S.L.U., a company operating in Spain from Grupo Ferrer Internacional, S.A. Tarbis Farma comes with a robust product portfolio and an extensive marketing network with well-experienced personnel in Retail business across Spain. The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and a seamless entry into the Retail, Hospital and Tender business channels in Spain.
Advt
Mr. A V Narasa Reddy, Executive Director of Hetero Labs Limited, stated that this acquisition fits very well with Hetero’s growth strategy in EU giving Amarox a platform to reach out to the customers in a robust way with the present portfolio and Hetero’s pipeline of products.
The buyer and seller were advised by Crowe and Deloitte respectively.
Read by
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions